DNA sequencing WGS and WXS data were newly generated for the MD Anderson Cancer Center, Duke University Hospital, Henry Ford Hospital, Case Western Reserve University, Chinese University of Hong Kong, Mayo Clinic, Northwestern Medicine, Olivia Newton-John Cancer Research Institute, University of California, San Francisco, Saint Joseph’s Hospital and Medical Center, Seoul National University and Luxembourg
Exploratory biomarker analyses were performed in 190 patients (nivolumab, 98 out of 229 (43%); placebo, 92 out of 232 (40%)) with evaluable paired tumour samples from screening and blood samples from ≥1 time point during the study for whole-exome sequencing (WES). These individuals constituted the biomarker-evaluable population. The most common reasons for exclusion were samples
